Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)
Crinetics Pharmaceuticals' quarterly Accumulated Depreciation came in at $9.6 million in Q2 2025, up 53.84% year-on-year from $6.2 million in Q2 2024, and up 10.95% quarter-over-quarter from $8.6 million in Q1 2025.
Crinetics Pharmaceuticals has reported Accumulated Depreciation for 9 years, with the latest figure at $9.6 million in Q2 2025.
- For the quarter ending Q2 2025, Accumulated Depreciation rose 53.84% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2025 stood at $9.6 million (up 53.84% YoY), and the FY2024 full-year result was $7.7 million, up 52.57% from the prior year.
- Accumulated Depreciation for Q2 2025 stood at $9.6 million, up from $8.6 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $9.6 million in Q2 2025, with the low at $3.0 million in Q1 2021.
- Average Accumulated Depreciation over 5 years is $5.2 million, with a median of $4.6 million recorded in 2023.
- Year-over-year, Accumulated Depreciation soared 62.02% in 2021 and rose 16.95% in 2023.
- Tracing CRNX's Accumulated Depreciation over 5 years: stood at $3.5 million in 2021, then advanced by 17.36% to $4.1 million in 2022, then grew by 24.09% to $5.1 million in 2023, then surged by 52.57% to $7.7 million in 2024, then grew by 23.98% to $9.6 million in 2025.
- The last three Accumulated Depreciation figures came in at $9.6 million (Q2 2025), $8.6 million (Q1 2025), and $7.7 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 9.59 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Dec 31, 2024 | 7.73 Mn |
| Sep 30, 2024 | 6.98 Mn |
| Jun 30, 2024 | 6.23 Mn |
| Mar 31, 2024 | 5.48 Mn |
| Dec 31, 2023 | 5.07 Mn |
| Sep 30, 2023 | 4.88 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 4.37 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 3.48 Mn |
| Sep 30, 2021 | 3.25 Mn |
| Mar 31, 2021 | 3.01 Mn |
| Dec 31, 2020 | 2.56 Mn |
| Sep 30, 2020 | 2.33 Mn |
| Jun 30, 2020 | 2.10 Mn |
| Mar 31, 2020 | 1.86 Mn |
| Dec 31, 2019 | 1.62 Mn |
| Sep 30, 2019 | 1.40 Mn |
| Jun 30, 2019 | 1.17 Mn |
| Mar 31, 2019 | 938,000.00 |
| Dec 31, 2018 | 741,000.00 |
| Sep 30, 2018 | 532,000.00 |
| Jun 30, 2018 | 428,000.00 |
| Dec 31, 2017 | 304,000.00 |